Drug-drug interactions in oncology : Why are they important and can they be minimized?BLOWER, Peter; DE WIT, Ronald; GOODIN, Susan et al.Critical reviews in oncology/hematology. 2005, Vol 55, Num 2, pp 117-142, issn 1040-8428, 26 p.Article

Potential drug-drug interactions in the medication of medical patients at hospital dischargeEGGER, Sabin S; DREWE, Jürgen; SCHLIENGER, Raymond G et al.European journal of clinical pharmacology. 2003, Vol 58, Num 11, pp 773-778, issn 0031-6970, 6 p.Article

Drug-drug interactions among recently hospitalised patients - frequent but mostly clinically insignificantGLINTBORG, Bente; ANDERSEN, Stig Ejdrup; DALHOFF, Kim et al.European journal of clinical pharmacology. 2005, Vol 61, Num 9, pp 675-681, issn 0031-6970, 7 p.Article

Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICUSPRIET, Isabel; MEERSSEMAN, Wouter; DE HOON, Jan et al.Intensive care medicine (Print). 2009, Vol 35, Num 4, pp 603-612, issn 0342-4642, 10 p.Article

Kinetic values for mechanism-based enzyme inhibition : Assessing the bias introduced by the conventional experimental protocolJIANSONG YANG; JAMEI, Masoud; ROWLAND YEO, Karen et al.European journal of pharmaceutical sciences. 2005, Vol 26, Num 3-4, pp 334-340, issn 0928-0987, 7 p.Article

Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxyl-propionic acid; NSC698215) in patients and in vitro : low potential for active or toxic metabolites or for drug-drug interactionsANDERSON, Lawrence W; COLLINS, Jerry M; KLECKER, Raymond W et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 4, pp 351-357, issn 0344-5704, 7 p.Article

Drug interaction of spirapril hydrochloride monohydrate and hydrochlorothiazide: A clinical study to compare the pharmacokinetics after administration of spirapril hydrochloride monohydrate tablets, hydrochlorothiazide tablets and feed combination bi-layer tabletsSCHÜRER, Michael; ERB, Katharina; JUNGE, Klaus et al.Arzneimittel-Forschung. 2003, Vol 53, Num 6, pp 414-419, issn 0004-4172, 6 p.Article

Effects of Steady-State Lopinavir/Ritonavir on the Pharmacokinetics of Pitavastatin in Healthy Adult VolunteersMORGAN, Roger E; CAMPBELL, Stuart E; SUEHIRA, Kazuhito et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 60, Num 2, pp 158-164, issn 1525-4135, 7 p.Article

A computerized system for detecting signals due to drug―drug interactions in spontaneous reporting systemsYIFENG QIAN; XIAOFEI YE; WENMIN DU et al.British journal of clinical pharmacology. 2010, Vol 69, Num 1, pp 67-73, issn 0306-5251, 7 p.Article

Detecting signals of drug-drug interactions in a spontaneous reports databaseTHAKRAR, Bharat T; GRUNDSCHOBER, Sabine Borel; DOESSEGGER, Lucette et al.British journal of clinical pharmacology. 2007, Vol 64, Num 4, pp 489-495, issn 0306-5251, 7 p.Article

Identification of severe potential drug-drug interactions using an Italian general-practitioner databaseMAGRO, L; CONFORTI, A; DEL ZOTTI, F et al.European journal of clinical pharmacology. 2008, Vol 64, Num 3, pp 303-309, issn 0031-6970, 7 p.Article

Prevalence and determinants of pharmacy shopping behaviourBUURMA, H; BOUVY, M. L; DE SMET, P. A. G. M et al.Journal of clinical pharmacy and therapeutics (Print). 2008, Vol 33, Num 1, pp 17-23, issn 0269-4727, 7 p.Article

Patterns of prescription drug use and incidence of drug―drug interactions in patients reporting to medical emergencyDHAMIJA, Puneet; BANSAL, Dipika; SRINIVASAN, Anand et al.Fundamental & clinical pharmacology. 2013, Vol 27, Num 2, pp 231-237, issn 0767-3981, 7 p.Article

Clinically important drug―drug interactions in primary careDHABALI, A. A. H; AWANG PHARM, R; ZYOUD, S. H et al.Journal of clinical pharmacy and therapeutics (Print). 2012, Vol 37, Num 4, pp 426-430, issn 0269-4727, 5 p.Article

Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibeDERKS, Michael; ABT, Markus; PHELAN, Mary et al.British journal of clinical pharmacology. 2010, Vol 70, Num 6, pp 825-833, issn 0306-5251, 9 p.Article

Maraviroc : in vitro assessment of drug-drug interaction potentialHYLAND, Ruth; DICKINS, Maurice; COLLINS, Claire et al.British journal of clinical pharmacology. 2008, Vol 66, Num 4, pp 498-507, issn 0306-5251, 10 p.Article

Interventions to Improve Anticoagulation With WarfarinARAUJO CASTRO, Tatiane; HEINECK, Isabela.Therapeutic drug monitoring. 2012, Vol 34, Num 2, pp 209-216, issn 0163-4356, 8 p.Article

N-in-1 Dosing Pharmacokinetics in Drug Discovery : Experience, Theoretical and Practical ConsiderationsKAN HE; MINGXIN QIAN; HANG ZENG et al.Journal of pharmaceutical sciences. 2008, Vol 97, Num 7, pp 2568-2580, issn 0022-3549, 13 p.Article

Recognition and management of potential drug-drug interactions in patients on internal medicine wardsVONBACH, Priska; DUBIED, André; BEER, Jürg H et al.European journal of clinical pharmacology. 2007, Vol 63, Num 11, pp 1075-1083, issn 0031-6970, 9 p.Article

Potentially inappropriate prescribing to the elderly: comparison of new protocol to Beers criteria with relation to hospitalizations for ADRsMATANOVIC, Suzana Mimica; VLAHOVIC-PALCEVSKI, Vera.European journal of clinical pharmacology. 2014, Vol 70, Num 4, pp 483-490, issn 0031-6970, 8 p.Article

Interactions and Monitoring of Antipsychotic DrugsHIEMKE, Christoph; PFUHLMANN, Bruno.Handbook of experimental pharmacology. 2012, Vol 212, pp 241-265, issn 0171-2004, 25 p.Article

PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicalsBOIS, Frédéric Y; JAMEI, Masoud; CLEWELL, Harvey J et al.Toxicology (Amsterdam). 2010, Vol 278, Num 3, pp 256-267, issn 0300-483X, 12 p.Conference Paper

Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4MOULY, Stéphane; MEUNE, Christophe; BERGMANN, Jean-Francois et al.Intensive care medicine (Print). 2009, Vol 35, Num 3, pp 417-429, issn 0342-4642, 13 p.Article

Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptorHARMSEN, S; MEIJERMAN, I; BEIJNEN, J. H et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 1, pp 35-43, issn 0344-5704, 9 p.Article

Effects of Laropiprant, a Selective Prostaglandin D₂ Receptor 1 Antagonist, on the Pharmacokinetics of RosiglitazoneSCHWARTZ, Jules I; STROH, Mark; BING GAO et al.Cardiovascular therapeutics (Print). 2009, Vol 27, Num 4, pp 239-245, issn 1755-5914, 7 p.Article